DOCSLIB.ORG

A Core Erythroid Transcriptional Network Is Repressed by a Master Regulator of Myelo-Lymphoid Differentiation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Core Erythroid Transcriptional Network Is Repressed by a Master Regulator of Myelo-Lymphoid Differentiation A core erythroid transcriptional network is repressed by a master regulator of myelo-lymphoid differentiation Sandeep N. Wontakala,1, Xingyi Guob,1, Cameron Smithc,2, Thomas MacCarthyc,d,2, Emery H. Bresnicke, Aviv Bergmanc, Michael P. Snyderf,g, Sherman M. Weissmanh,3, Deyou Zhengb,i,3, and Arthur I. Skoultchia,3 Departments of aCell Biology, bNeurology, cSystems and Computational Biology, and iGenetics and Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461; dDepartment of Applied Mathematics and Statistics, State University of New York, Stony Brook, NY 11794; eWisconsin Institutes for Medical Research, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705; hDepartment of Genetics, Yale University School of Medicine, New Haven, CT 06520; fDepartment of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06520; and gDepartment of Genetics, Stanford University, Stanford, CA 94305 Contributed by Sherman M. Weissman, December 29, 2011 (sent for review October 10, 2011) Two mechanisms that play important roles in cell fate decisions are PU.1, is a negative regulator of terminal erythroid differentiation control of a “core transcriptional network” and repression of alter- (16–19). Surprisingly, PU.1 was found to occupy more genes in native transcriptional programs by antagonizing transcription fac- erythroid progenitors than the three erythroid-promoting factors tors. Whether these two mechanisms operate together is not (20). However, the extent of overlap between the genes bound by known. Here we report that GATA-1, SCL, and Klf1 form an erythroid PU.1 and the three erythroid factors is not known. core transcriptional network by co-occupying >300 genes. Impor- In this study, we provide genomic evidence for the existence of tantly, we find that PU.1, a negative regulator of terminal erythroid a core erythroid network of >300 genes that are co-occupied and differentiation, is a highly integrated component of this network. regulated by GATA-1, SCL, and Klf1. This network has charac- GATA-1, SCL, and Klf1 act to promote, whereas PU.1 represses ex- teristic features of core transcriptional networks, including pression of many of the core network genes. PU.1 also represses the a multi-input motif and feed-forward loops. Furthermore, we also genes encoding GATA-1, SCL, Klf1, and important GATA-1 cofactors. find that PU.1 binds to and represses most of the genes in this Conversely, in addition to repressing PU.1 expression, GATA-1 also network, indicating that PU.1 is a highly integrated negative > binds to and represses 100 PU.1 myelo-lymphoid gene targets in regulator of the core erythroid network. Conversely, we also find erythroid progenitors. Mathematical modeling further supports that that GATA-1 binds to and represses >100 PU.1 myelo-lymphoid this dual mechanism of repressing both the opposing upstream acti- gene targets in erythroid progenitors. Finally, mathematical vator and its downstream targets provides a synergistic, robust fi modeling reveals that the dual mechanism used by both GATA-1 mechanism for lineage speci cation. Taken together, these results and PU.1 to repress an alternative lineage-specific transcriptional amalgamate two key developmental principles, namely, regulation program provides a robust mechanism for lineage specification. of a core transcriptional network and repression of an alternative transcriptional program, thereby enhancing our understanding of Results the mechanisms that establish cellular identity. GATA-1 Preferentially Binds Distal to Genes. To begin to investigate the possible existence of a “core erythroid network,” we carried ChIP sequencing | erythropoiesis | cross antagonism out ChIP-Seq experiments on endogenous GATA-1 in normal, murine ES cell-derived erythroid progenitors (ES-EP) (21) in lthough cells have hundreds of transcriptional regulators, the both proliferating and differentiating conditions. The following Afunction of only a few key factors has been proposed to be results indicate that our ChIP-Seq data are of high quality. critical for establishing and/or maintaining cellular identity (1). Several well-established GATA-1 binding sites are found in the Studies in just a few cell types, particularly embryonic stem (ES) dataset, including binding sites in the β-globin locus control re- cells, support this concept (2, 3). In ES cells, the “core pluri- C ” ∼ gion (LCR) (Fig. S1 ). GATA-1 bound regions in both pro- potency factors Oct4, Nanog, and Sox2 co-occupy 300 genes liferating and differentiating conditions are highly enriched with that are enriched for developmental regulators and genes in- a characteristic GATA-1 binding motif (Fig. S1D), similar to that volved in self-renewal (2). The gene network formed by these observed in recent studies (12, 13). Using quantitative chromatin three core ES cell factors exhibits several types of regulatory immunoprecipitation (qChIP) for GATA-1, we validated 100% circuitry including a multi-input motif and feed-forward loops (2, (18/18) of the sites bound in both proliferating and differenti- 3). However, whether such a “core transcriptional network” exists ating conditions (Fig. S2). in hematopoietic cells is not known. Several recent reports describe genome-wide occupancy of GATA-1, SCL, and Klf1 are three essential erythroid pro- GATA-1 in several murine and human erythroid cell lines (12, moting transcription factors that play critical roles in establishing fi erythroid identity through the up-regulation of erythroid-specific 13, 22, 23). Similar to these other reports, we nd that GATA-1 genes (4, 5). GATA-1 regulates expression of some erythroid- specific genes, such as globin genes, in association with SCL (6–8) and Klf1 (9–11). Recent studies of transcription factor occupancy Author contributions: S.N.W., S.M.W., and A.I.S. designed research; S.N.W., C.S., and T.M. performed research; S.N.W., X.G., C.S., T.M., E.H.B., S.M.W., M.P.S., and D.Z. contributed in erythroid progenitors by chromatin immunoprecipitation and new reagents/analytic tools; S.N.W., X.G., C.S., T.M., A.B., S.M.W., D.Z., and A.I.S. analyzed high-throughput sequencing (ChIP-Seq) revealed that GATA-1 data; and X.G., C.S., T.M., S.N.W., D.Z., and A.I.S. wrote the paper. bound regions are enriched for SCL binding elements (12, 13), The authors declare no conflict of interest. SCL bound regions are enriched for potential GATA-1 binding Database deposition: The data reported in this paper have been deposited in the Gene sites (14), and Klf1 occupied regions are enriched for putative Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE35385). GATA-1 and SCL binding motifs (15). Although there is evidence 1S.N.W. and X.G. contributed equally to this work. that these three factors cooperatively regulate certain erythroid- 2C.S. and T.M. contributed equally to this work. fi speci c genes, whether they form a network with features similar 3To whom correspondence may be addressed. E-mail: [email protected], to the ES cell core transcriptional network is not known. [email protected], or [email protected]. Whereas GATA-1, SCL, and Klf1 are essential for erythroid This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. development, the myelo-lymphoid promoting transcription factor, 1073/pnas.1121019109/-/DCSupplemental. 3832–3837 | PNAS | March 6, 2012 | vol. 109 | no. 10 www.pnas.org/cgi/doi/10.1073/pnas.1121019109 Downloaded by guest on September 27, 2021 most often binds distal to gene promoters; 80–90% of GATA-1 progenitors (FL-EP) (14, 15), using the same criterion (−20 kb occupied sites are in intragenic or intergenic regions, and <20% TSS to +10 kb TES). We found that each factor binds to a large of bound regions are within 2 kb of transcription start sites (TSS) number of genes independent of the other two factors. GATA-1 (Fig. S1B). However, in contrast to the results in one of the binds 3,560 (490 + 1,810 + 1,260) genes independently, and SCL studies with murine erythroleukemia (MEL) cells (22), we find and Klf1 bind independently to 421 and 230 genes, respectively that the number of sites occupied by GATA-1 increases during (Fig. 1A). Importantly, however, the analysis revealed that 313 differentiation of erythroid progenitors, from 6,600 sites in (263 + 8 + 42) genes were co-occupied by the three factors (P − proliferating progenitors to 10,600 sites in differentiating cells. In value <2.2 × 10 16) (Fig. 1B), which is strikingly similar to the addition, we find that the magnitude of many GATA-1 ChIP-Seq number of genes that are co-occupied by the three core ES cell peaks increases during differentiation at sites occupied in both factors (353) (2). Furthermore, there is a strong bias for the three proliferating and differentiating cells (Fig. S1 A and C). These erythroid factors to bind in close proximity (within 200 bp) to one results provide unique genome-wide occupancy maps of GATA- another near these 313 genes (Fig. 1B). This bias is significantly 1 in normal erythroid progenitors, in both proliferating and different from the pairwise peak distances computed for the genes bound by only two of the three factors (Fisher’s exact test, differentiating conditions. − P value <2.2 × 10 16). This finding suggests that the three ery- Associating GATA-1 Occupancy with Gene Regulation. We next throid factors form a dense overlapping regulon and, more sought to understand the relationship between GATA-1 bound specifically, a multi-input motif, similar to the core networks sites and genes. Because there is no well-established method for described in ES, pancreatic, and liver cells (2, 3). We also find assigning transcription factor bound sites to genes (24, 25), we that the genes co-occupied by GATA-1, SCL, and Klf1 exhibit tested four different criteria and found that assigning genes to the largest changes in gene expression during the differentiation GATA-1 peaks that lie within the region spanning −20 kb of TSS of both ES-EP and MEL cells (Fig.
Load more

Recommended publications
  • The Role of PU.1 and GATA-1 Transcription Factors During Normal and Leukemogenic Hematopoiesis
    Leukemia (2010) 24, 1249–1257 & 2010 Macmillan Publishers Limited All rights reserved 0887-6924/10 www.nature.com/leu REVIEW The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis P Burda1, P Laslo2 and T Stopka1,3 1Department of Pathophysiology and Center of Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic; 2Section of Experimental Haematology, Leeds Institute of Molecular Medicine, University of Leads, St James’s University Hospital, Leeds, UK and 31st Department of Medicine-Hematology, General University Hospital, Prague, Czech Republic Hematopoiesis is coordinated by a complex regulatory network Additional domains include an N-terminal acidic domain and a of transcription factors and among them PU.1 (Spi1, Sfpi1) glutamine-rich domain, both involved in transcriptional activa- represents a key molecule. This review summarizes the tion, as well as a PEST domain involved in protein–protein indispensable requirement of PU.1 during hematopoietic cell fate decisions and how the function of PU.1 can be modulated interactions. PU.1 protein can be modified post-translationally by protein–protein interactions with additional factors. The by phosporylation at serines 41 (N-terminal acidic domain) and mutual negative regulation between PU.1 and GATA-1 is 142 and 148 (PEST domain), which results in augmented detailed within the context of normal and leukemogenic activity. hematopoiesis and the concept of ‘differentiation therapy’ to The PU.1 protein can physically interact with a variety of restore normal cellular differentiation of leukemic cells is regulatory factors including (i) general transcription factors discussed. Leukemia (2010) 24, 1249–1257; doi:10.1038/leu.2010.104; (TFIID, TBP), (ii) early hematopoietic transcription factors published online 3 June 2010 (GATA-2 and Runx-1), (iii) erythroid factor (GATA-1) and (iv) Keywords: PU.1; leukemia differentiation; GATA-1; chromatin; non-erythroid factors (C/EBPa, C/EBPb, IRF4/8 and c-Jun).
    [Show full text]
  • Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Co-Regulator in Invasive 6 Lobular Carcinoma of the Breast 7 8 Evelyn K
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.16.423142; this version posted December 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Running Title: MDC1 co-regulates ER in ILC 2 3 Research article 4 5 Mediator of DNA damage checkpoint 1 (MDC1) is a novel estrogen receptor co-regulator in invasive 6 lobular carcinoma of the breast 7 8 Evelyn K. Bordeaux1+, Joseph L. Sottnik1+, Sanjana Mehrotra1, Sarah E. Ferrara2, Andrew E. Goodspeed2,3, James 9 C. Costello2,3, Matthew J. Sikora1 10 11 +EKB and JLS contributed equally to this project. 12 13 Affiliations 14 1Dept. of Pathology, University of Colorado Anschutz Medical Campus 15 2Biostatistics and Bioinformatics Shared Resource, University of Colorado Comprehensive Cancer Center 16 3Dept. of Pharmacology, University of Colorado Anschutz Medical Campus 17 18 Corresponding author 19 Matthew J. Sikora, PhD.; Mail Stop 8104, Research Complex 1 South, Room 5117, 12801 E. 17th Ave.; Aurora, 20 CO 80045. Tel: (303)724-4301; Fax: (303)724-3712; email: [email protected]. Twitter: 21 @mjsikora 22 23 Authors' contributions 24 MJS conceived of the project. MJS, EKB, and JLS designed and performed experiments. JLS developed models 25 for the project. EKB, JLS, SM, and AEG contributed to data analysis and interpretation. SEF, AEG, and JCC 26 developed and performed informatics analyses. MJS wrote the draft manuscript; all authors read and revised the 27 manuscript and have read and approved of this version of the manuscript.
    [Show full text]
  • 5045.Full.Pdf
    IFN Consensus Sequence Binding Protein (Icsbp) Is Critical for Eosinophil Development This information is current as Maja Milanovic, Grzegorz Terszowski, Daniela Struck, of September 28, 2021. Oliver Liesenfeld and Dirk Carstanjen J Immunol 2008; 181:5045-5053; ; doi: 10.4049/jimmunol.181.7.5045 http://www.jimmunol.org/content/181/7/5045 Downloaded from References This article cites 47 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/181/7/5045.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology IFN Consensus Sequence Binding Protein (Icsbp) Is Critical for Eosinophil Development1 Maja Milanovic,2* Grzegorz Terszowski,2† Daniela Struck,2‡ Oliver Liesenfeld,‡ and Dirk Carstanjen3* IFN consensus sequence binding protein (Icsbp) (IFN response factor-8) is a hematopoietic transcription factor with dual functions in myelopoiesis and immunity.
    [Show full text]
  • Transcriptome Analysis of Gravitational Effects on Mouse Skeletal Muscles Under Microgravity and Artificial 1 G Onboard Environm
    www.nature.com/scientificreports OPEN Transcriptome analysis of gravitational efects on mouse skeletal muscles under microgravity and artifcial 1 g onboard environment Risa Okada1,2, Shin‑ichiro Fujita3,4, Riku Suzuki5,6, Takuto Hayashi3,5, Hirona Tsubouchi5, Chihiro Kato5,7, Shunya Sadaki5, Maho Kanai5,6, Sayaka Fuseya3,5, Yuri Inoue3,5, Hyojung Jeon5, Michito Hamada5, Akihiro Kuno5,6, Akiko Ishii8, Akira Tamaoka8, Jun Tanihata9, Naoki Ito10, Dai Shiba1,2, Masaki Shirakawa1,2, Masafumi Muratani1,4, Takashi Kudo1,5* & Satoru Takahashi1,5* Spacefight causes a decrease in skeletal muscle mass and strength. We set two murine experimental groups in orbit for 35 days aboard the International Space Station, under artifcial earth‑gravity (artifcial 1 g; AG) and microgravity (μg; MG), to investigate whether artifcial 1 g exposure prevents muscle atrophy at the molecular level. Our main fndings indicated that AG onboard environment prevented changes under microgravity in soleus muscle not only in muscle mass and fber type composition but also in the alteration of gene expression profles. In particular, transcriptome analysis suggested that AG condition could prevent the alterations of some atrophy‑related genes. We further screened novel candidate genes to reveal the muscle atrophy mechanism from these gene expression profles. We suggest the potential role of Cacng1 in the atrophy of myotubes using in vitro and in vivo gene transductions. This critical project may accelerate the elucidation of muscle atrophy mechanisms. Gravity is the most constant factor afecting the entire process of evolution of organisms on Earth. As adapting to a changing environment is key for any organism’s survival, the constant mechanical stimulus of gravitational force has been shared by all organisms on Earth through evolution 1.
    [Show full text]
  • Expression of Wilms Tumor 1 Gene Distinguishes Vascular Malformations from Proliferative Endothelial Lesions
    OBSERVATION Expression of Wilms Tumor 1 Gene Distinguishes Vascular Malformations From Proliferative Endothelial Lesions Leslie P. Lawley, MD; Francesca Cerimele, MD, PhD; Sharon W. Weiss, MD; Paula North, MD; Cynthia Cohen, MD; Harry P. W. Kozakewich, MD; John B. Mulliken, MD; Jack L. Arbiser, MD, PhD Background: Vascular malformations and hemangio- Observations: The biochemical differences between mas, which are endothelial lesions of childhood, may re- hemangiomas, which involute, and vascular malforma- sult in considerable morbidity because they can cause dis- tions, which do not involute, are not well understood. comfort and functional impairment and have a negative We found that the transcription factor encoded by the affect on the patient’s appearance. Although vascular mal- Wilms tumor 1 (WT1) gene is expressed in the endothe- formations may initially appear very similar to heman- lium of hemangiomas but not in vascular malforma- giomas, they have distinct clinical courses. Infantile hem- tions. angiomas progress through 3 stages: proliferative, involuting, and involuted. The proliferative phase is char- Conclusions: Defects in WT1 signaling may underlie the acterized by clinical growth. Once hemangiomas reach inability of malformation endothelial cells to undergo their maximum size, they begin to regress or involute. physiologic apoptosis and remodeling. The availability Histologically, this stage is characterized by endothelial of WT1 staining in hospital laboratories may allow the apoptosis. Finally, the involuted stage of the heman- clinician to distinguish hemangiomas from vascular mal- gioma occurs when the original lesion is replaced by a formations and thus to give appropriate therapy to the connective tissue remnant. In contrast to hemangio- patient. mas, vascular malformations do not involute but con- tinue to enlarge as the patient grows.
    [Show full text]
  • Corrupted DNA-Binding Specificity and Ectopic Transcription Underpin Dominant Neomorphic Mutations in KLF/SP Transcription Factors Melissa D
    Ilsley et al. BMC Genomics (2019) 20:417 https://doi.org/10.1186/s12864-019-5805-z RESEARCH ARTICLE Open Access Corrupted DNA-binding specificity and ectopic transcription underpin dominant neomorphic mutations in KLF/SP transcription factors Melissa D. Ilsley1,2, Stephen Huang1,2, Graham W. Magor1,4, Michael J. Landsberg3, Kevin R. Gillinder1,4*† and Andrew C. Perkins1,4† Abstract Background: Mutations in the transcription factor, KLF1, are common within certain populations of the world. Heterozygous missense mutations in KLF1 mostly lead to benign phenotypes, but a heterozygous mutation in a DNA-binding residue (E325K in human) results in severe Congenital Dyserythropoietic Anemia type IV (CDA IV); i.e. an autosomal-dominant disorder characterized by neonatal hemolysis. Results: To investigate the biochemical and genetic mechanism of CDA IV, we generated murine erythroid cell lines that harbor tamoxifen-inducible (ER™) versions of wild type and mutant KLF1 on a Klf1−/− genetic background. Nuclear translocation of wild type KLF1 results in terminal erythroid differentiation, whereas mutant KLF1 results in hemolysis without differentiation. The E to K variant binds poorly to the canonical 9 bp recognition motif (NGG- GYG-KGG) genome-wide but binds at high affinity to a corrupted motif (NGG-GRG-KGG). We confirmed altered DNA-binding specificity by quantitative in vitro binding assays of recombinant zinc-finger domains. Our results are consistent with previously reported structural data of KLF-DNA interactions. We employed 4sU-RNA-seq to show that a corrupted transcriptome is a direct consequence of aberrant DNA binding. Conclusions: Since all KLF/SP family proteins bind DNA in an identical fashion, these results are likely to be generally applicable to mutations in all family members.
    [Show full text]
  • Letters to the Editor
    LETTERS TO THE EDITOR The significant upregulation of Gata1 and EpoR mRNA Mice over-expressing human erythropoietin expression in hEPO over-expressing tg6 mice was con - indicate that erythropoietin enhances expression firmed by analyzing the spleen as a major source of of its receptor via up-regulated Gata1 and Tal1 hematopoiesis (Figure 2A and B). To further dissect the complexity of changes in the transcriptional network, the analysis of Myb mRNA expression served as marker for The development of medullary hematopoiesis is char - adult definitive erythroblasts, 10 showing significantly acterized by a specific expression profile of hematopoiet - ic transcription factors, including GATA transcription fac - tors. At mid-gestation, when hematopoiesis is newly A GATA 1 2 established in the bone marrow of human fetuses, initial - wt ly high GATA2 expression becomes subsequently down- regulated, while GATA1 expression increases in parallel. 1 1.5 Both transcription factors bind to overlapping sets of tg6 hematopoietic downstream target genes, often at distinct 1 sites, to regulate the balance between proliferation and differentiation. Chromatin occupancy by GATA1 and 0.5 GATA2 can change in the course of hematopoietic differ - entiation, leading to the so-called GATA switch. 2 Thus, a 0 n d7 d21 d49 i spatio-temporal regulation of GATA1 or GATA2 activities t c is required within lineage-specific differentiation. During a - erythroid differentiation GATA1 expression peaks at the b B GATA 2 3 o level of colony-forming units (CFU-E), where erythro - t 2 e poietin (Epo) exerts most specifically its effects, but v i t blocks terminal maturation if constitutively over- a 1.5 l 4 e expressed.
    [Show full text]
  • Enhancer of WT1 Gene Is Essential for Its Transcription in Acute Leukemia and Solid Tumor Cell Lines
    Leukemia (2009) 23, 1270–1277 & 2009 Macmillan Publishers Limited All rights reserved 0887-6924/09 $32.00 www.nature.com/leu ORIGINAL ARTICLE GATA-1 and GATA-2 binding to 30 enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines A Furuhata1, M Murakami1, H Ito1, S Gao1, K Yoshida1, S Sobue2, R Kikuchi3, T Iwasaki3, A Takagi1, T Kojima1, M Suzuki4, A Abe5, T Naoe5 and T Murate1 1Department of Medical Technology, Nagoya University Graduate School of Health Sciences, Nagoya, Japan; 2Department of Pathology, College of Life and Health Sciences, Chubu University, Kasugai, Japan; 3Department of Laboratory Medicine, Nagoya University School of Medicine, Nagoya, Japan; 4Division of Molecular Carcinogenesis, Nagoya University Graduate School of Medicine, Nagoya, Japan and 5Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan Although oncogenic functions and the clinical significance of WT1 have been well documented, its gene-expression mecha- Wilms tumor 1 (WT1) have been extensively studied in acute nism remains undetermined. leukemia, the regulatory mechanism of its transcription still 13 remains to be determined. We found a significant correlation In the promoter analysis of WT1 gene, Cohen et al. reported among the amounts of WT1, GATA-1 and GATA-2 mRNAs from the importance of Sp1 for mRNA expression, although the leukemia and solid tumor cell lines. Overexpression and small promoter region may not determine the tissue-specific manner interfering RNA (siRNA) transfection experiments of GATA-1 of WT1 expression.13,14 Regarding this point, the 30 enhancer and GATA-2 showed that these GATA transcription factors located 450 kb downstream of the promoter was identified as could induce WT1 expression.
    [Show full text]
  • Drosophila and Human Transcriptomic Data Mining Provides Evidence for Therapeutic
    Drosophila and human transcriptomic data mining provides evidence for therapeutic mechanism of pentylenetetrazole in Down syndrome Author Abhay Sharma Institute of Genomics and Integrative Biology Council of Scientific and Industrial Research Delhi University Campus, Mall Road Delhi 110007, India Tel: +91-11-27666156, Fax: +91-11-27662407 Email: [email protected] Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 Running head: Pentylenetetrazole mechanism in Down syndrome 1 Abstract Pentylenetetrazole (PTZ) has recently been found to ameliorate cognitive impairment in rodent models of Down syndrome (DS). The mechanism underlying PTZ’s therapeutic effect is however not clear. Microarray profiling has previously reported differential expression of genes in DS. No mammalian transcriptomic data on PTZ treatment however exists. Nevertheless, a Drosophila model inspired by rodent models of PTZ induced kindling plasticity has recently been described. Microarray profiling has shown PTZ’s downregulatory effect on gene expression in fly heads. In a comparative transcriptomics approach, I have analyzed the available microarray data in order to identify potential mechanism of PTZ action in DS. I find that transcriptomic correlates of chronic PTZ in Drosophila and DS counteract each other. A significant enrichment is observed between PTZ downregulated and DS upregulated genes, and a significant depletion between PTZ downregulated and DS dowwnregulated genes. Further, the common genes in PTZ Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 downregulated and DS upregulated sets show enrichment for MAP kinase pathway. My analysis suggests that downregulation of MAP kinase pathway may mediate therapeutic effect of PTZ in DS. Existing evidence implicating MAP kinase pathway in DS supports this observation.
    [Show full text]
  • GATA1 Gene GATA Binding Protein 1
    GATA1 gene GATA binding protein 1 Normal Function The GATA1 gene provides instructions for making a protein that attaches (binds) to specific regions of DNA and helps control the activity of many other genes. On the basis of this action, the GATA1 protein is known as a transcription factor. The GATA1 protein is involved in the specialization (differentiation) of immature blood cells. To function properly, these immature cells must differentiate into specific types of mature blood cells. By binding to DNA and interacting with other proteins, the GATA1 protein regulates the growth and division (proliferation) of immature red blood cells and platelet-precursor cells (megakaryocytes) to facilitate their differentiation. Red blood cells help carry oxygen to various tissues throughout the body and platelets aid in blood clotting. The GATA1 protein is also important for the maturation of several types of white blood cells that help fight infection, including eosinophils, mast cells, and dendritic cells. Two versions of the GATA1 protein are produced from the GATA1 gene: a regular length protein and a shorter version called GATA1s. The GATA1s protein lacks a specific region called the transactivation domain. Although the specific function of this region is unclear, researchers believe that it interacts with other proteins to modify GATA1 protein function. Health Conditions Related to Genetic Changes Dyserythropoietic anemia and thrombocytopenia At least eight different mutations in the GATA1 gene have been found to cause dyserythropoietic anemia and thrombocytopenia. Most of these mutations change a single protein building block (amino acid) in the GATA1 protein. GATA1 gene mutations disrupt the protein's ability to bind with DNA or interact with other proteins.
    [Show full text]
  • Germline Mutations in Etv6 Result in Autosomal Dominant
    GERMLINE MUTATIONS IN ETV6 RESULT IN AUTOSOMAL DOMINANT THROMBOCYTOPENIA By LEILA J. NOETZLI B.S., University of California San Diego, 2007 A thesis submitted to the Faculty of the Graduate School of the University of Colorado in partial fulfillment of the requirements for the degree of Doctor of Philosophy Human Medical Genetics and Genomics Program 2017 This thesis for the Doctor of Philosophy degree by Leila J. Noetzli has been approved for the Human Medical Genetics and Genomics Program by Robert Sclafani, Chair Jorge Di Paola, Advisor Jay Hesselberth Richard Spritz Rytis Prekeris Date: May 19, 2017 ii Noetzli, Leila J. (Ph.D., Human Medical Genetics and Genomics) Germline mutations in ETV6 result in autosomal dominant thrombocytopenia Thesis directed by Associate Professor Jorge Di Paola ABSTRACT Whole exome sequencing on a family with autosomal dominant thrombocytopenia and two occurrences of acute lymphoblastic leukemia (ALL) of unknown cause identified a heterozygous single nucleotide change in the gene ETV6, encoding a p.Pro214Leu amino acid substitution. We screened families with the same phenotype and found mutations in ETV6 in two additional families: one with the identical p.Pro214Leu mutation and one with a p.Arg418Gly substitution. ETV6 is a transcriptional repressor that functions through self-oligomerization and is essential for hematopoietic stem cell proliferation and platelet production in mice. Our report was among the first to describe pathogenic germline mutations in ETV6. Functional characterization of the corresponding ETV6 protein mutations showed aberrant cytoplasmic localization, impaired transcriptional repression, and delayed megakaryocyte maturation. Furthermore, we found that mutant ETV6 protein oligomerizes with WT ETV6 and sequesters it from the nucleus suggesting a dominant negative mechanism.
    [Show full text]
  • Global Analysis of Estrogen Receptor Beta Binding to Breast Cancer Cell Genome Reveals an Extensive Interplay with Estrogen Rece
    Grober et al. BMC Genomics 2011, 12:36 http://www.biomedcentral.com/1471-2164/12/36 RESEARCHARTICLE Open Access Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation Oli MV Grober1†, Margherita Mutarelli1†, Giorgio Giurato1, Maria Ravo1,2, Luigi Cicatiello1, Maria Rosaria De Filippo1, Lorenzo Ferraro1, Giovanni Nassa1,2, Maria Francesca Papa1, Ornella Paris1, Roberta Tarallo1,2, Shujun Luo3, Gary P Schroth3, Vladimir Benes4, Alessandro Weisz1,2* Abstract Background: Estrogen receptors alpha (ERa) and beta (ERb) are transcription factors (TFs) that mediate estrogen signaling and define the hormone-responsive phenotype of breast cancer (BC). The two receptors can be found co-expressed and play specific, often opposite, roles, with ERb being able to modulate the effects of ERa on gene transcription and cell proliferation. ERb is frequently lost in BC, where its presence generally correlates with a better prognosis of the disease. The identification of the genomic targets of ERb in hormone-responsive BC cells is thus a critical step to elucidate the roles of this receptor in estrogen signaling and tumor cell biology. Results: Expression of full-length ERb in hormone-responsive, ERa-positive MCF-7 cells resulted in a marked reduction in cell proliferation in response to estrogen and marked effects on the cell transcriptome. By ChIP-Seq we identified 9702 ERb and 6024 ERa binding sites in estrogen-stimulated cells, comprising sites occupied by either ERb,ERa or both ER subtypes. A search for TF binding matrices revealed that the majority of the binding sites identified comprise one or more Estrogen Response Element and the remaining show binding matrixes for other TFs known to mediate ER interaction with chromatin by tethering, including AP2, E2F and SP1.
    [Show full text]